Efficacy of anti-death receptor 5 (DR5) antibody (TRA-8) against primary human ovarian carcinoma using a novel ex vivo tissue slice model

Gynecologic Oncology

Volumn 105, Issue 2, 2007, Pages 291-298

  Estes, Jacob M ^a   Oliver, Patsy G ^b   Straughn Jr , J Michael ^a   Zhou, Tong ^c   Wang, Wenquan ^c   Grizzle, William E ^d   Alvarez, Ronald D ^a   Stockard, Cecil R ^d   LoBuglio, Albert F ^c   Buchsbaum, Donald J ^b  

^a University of Alabama   (United States)

^b The University of Alabama at Birmingham   (United States)

^c University of Alabama at Birmingham   (United States)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Death Receptor 5; DR5; Krumdieck slicer; Ovarian cancer slices; TRA 8; TRAIL; Tumor slices

Indexed keywords

ADENOSINE TRIPHOSPHATE; CASPASE 3; CASPASE 8; CASPASE 9; DEATH RECEPTOR 5; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY SP6; MONOCLONAL ANTIBODY TRA 8; TUMOR NECROSIS FACTOR RELATED APOPTOSIS INDUCING LIGAND; UNCLASSIFIED DRUG;

ADULT; AGED; ANTIGEN EXPRESSION; APOPTOSIS; ARTICLE; CELL DEATH; CELL KILLING; CELL PROLIFERATION; CELL VIABILITY; CLINICAL ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DEVICE; DRUG EFFICACY; DRUG MECHANISM; ENZYME ACTIVATION; EX VIVO STUDY; FEMALE; HUMAN; HUMAN TISSUE; IC 50; IMMUNOHISTOCHEMISTRY; NICK END LABELING; NONLINEAR SYSTEM; OVARY CARCINOMA; OVARY TUMOR; PRIORITY JOURNAL; STAINING; TISSUE SLICE; WESTERN BLOTTING;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; BLOTTING, WESTERN; DRUG SCREENING ASSAYS, ANTITUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INHIBITORY CONCENTRATION 50; MIDDLE AGED; OVARIAN NEOPLASMS; RECEPTORS, TNF-RELATED APOPTOSIS-INDUCING LIGAND;

EID: 34247132169     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2006.12.033     Document Type: Article

References (38)

1. Jemal A., Siegel R., Ward E., Murray T., Xu J., Smigal C., et al. Cancer statistics. CA J Cancer Clin. 56 (2006) 106-130
2. Chi D.S., and Sabbatini P. Advanced ovarian cancer. Curr. Treat Options Oncol. 1 (2000) 139-146
3. Bookman M.A., McGuire III W.P., Kilpatrick D., et al. Carboplatin and paclitaxel in ovarian carcinoma: a phase I study of the Gynecologic Oncology Group. J. Clin. Oncol. 14 (1996) 1895-1902
4. McGuire W.P., Hoskins W.J., Brady M.F., et al. Cycophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N. Engl. J. Med. 334 (1996) 1-6
5. Ozols R.F., Bundy B.N., Greer B.E., et al. Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J. Clin. Oncol. 21 (2003) 3194-3200
6. Herzog T.J. Recurrent ovarian cancer: how important is it to treat disease progression?. Clin. Cancer Res. 10 (2004) 7439-7449
7. Monk B.J., Choi D.C., Pugmire G., and Burger R.A. Activity of bevacizumab (rhuMAB VEGF) in advanced refractory epithelial ovarian carcinoma. Gynecol. Oncol. 96 (2005) 902-905
8. Cohn D.E., Valmadre S., Resnick K.E., Eaton L.A., Copeland L.J., and Fowler J.M. Bevacizumab and weekly taxane chemotherapy demonstrates activity in refractory ovarian cancer. Gynecol. Oncol. 102 (2006) 134-139
9. Wiley S.R., Schooley K., Smolak P.J., et al. Identification and characterization of a new member of the TNF family that induces apoptosis. Immunity 3 (1995) 673-682
10. Daniel P.T., and Krammer P.H. Activation induces sensitivity toward APO-1 (CD95)-mediated apoptosis in human B cells. J. Immunol. 152 (1994) 5624-5632
11. Chaudhary P.M., Eby M., Jasmin A., Bookwalter A., Murray J., and Hood L. Death receptor 5, a new member of the TNFR family, and DR4 induce FADD-dependent apoptosis and activate the NF-κB pathway. Immunity 7 (1997) 821-830
12. Marsters S.A., Sheridan J.P., Pitti R.M., Huang A., Skubatch M., Baldwin D., et al. A novel receptor for Apo2/TRAIL contains a truncated death domain. Curr. Biol. 7 (1997) 1003-1006
13. Pan G., O'Rourke K., Chinnaiyan A.M., Gentz R., Ebner R., Ni J., et al. The receptor for the cytotoxic ligand TRAIL. Science 276 (1997) 111-113
14. Walczak H., Degli-Esposti M.A., Johnson R.S., Smolak P.J., Waugh J.Y., Boiani N., et al. TRAIL-R2: a novel apoptosis-mediating receptor for TRAIL. EMBO J. 16 (1997) 5386-5397
15. Ashkenazi A. Targeting death and decoy receptors of the tumour-necrosis factor superfamily. Nat. Rev., Cancer 2 (2002) 420-430
16. Jo M., Kim T.-H., Seol D.-W., Esplen J.E., Dorko K., Billiar T.R., et al. Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis inducing ligand. Nat. Med. 6 (2000) 564-567
17. Lawrence D., Shahrokh Z., Marsters S., Achilles K., Shih D., Mounho B., et al. Differential hepatocyte toxicity of recombinant Apo2/TRAIL versions. Nat. Med. 7 (2001) 383-385
18. Ichikawa K., Liu W., Zhao L., Wang Z., Liu D., Ohtsuka T., et al. Tumoricidal activity of a novel anti-human DR5 monoclonal antibody without hepatocyte toxicity. Nat. Med. 7 (2001) 954-960
19. Buchsbaum D.J., Zhou T., Grizzle W.E., Oliver P.G., Hammond C.J., Zhang S., et al. Antitumor efficacy of TRA-8 anti-DR5 monoclonal antibody alone or in combination with chemotherapy and/or radiation therapy in a human breast cancer model. Clin. Cancer Res. 9 (2003) 3731-3741
20. Straughn J.M., Oliver P.G., Zhou T., Wang W., Alvarez R.D., Grizzle W.E., and Buchsbaum D.J. Antitumor activity of TRA-8 anti-death receptor 5 (DR5) monoclonal antibody in combination with chemotherapy and radiation therapy in a cervical cancer model. Gynecol. Oncol. 101 (2006) 46-54
21. Kirby T.O., River A., Rein D., Wang M., Ulasov I., Breidenbach M., Kataram M., et al. A novel ex vivo model system for evaluation of conditionally replicative adenoviruses therapeutic efficacy and toxicity. Clin. Cancer Res. 10 (2004) 8697-8703
22. Krumdieck C.L., dos Santos J.E., and Ho K.J. A new instrument for the rapid preparation of tissue slices. Anal. Biochem. 104 (1980) 118-123
23. Cree I.A., and Andreotti P.E. Measurement of cytotoxicity by ATP-based luminescence assay in primary cell cultures and cell lines. Toxicol. In Vitro 11 (1997) 553-556
24. Poczatek R.B., Myers R.B., Manne U., Oelschlager D., Weiss H.L., Bostwick D.G., and Grizzle W.E. EpCAM levels in prosatic adenocarcinoma and prostatic intraepithelial neoplasia. J. Urol. 162 (1999) 1462-1466
25. Grizzle W.E. Tissue resources in the detection and evaluation of markers. In: Srivastava S. (Ed). Early detection of cancer: molecular markers (1997), Futura Publishing Co. Inc. 69-76
26. Grizzle W.E., Myers R.B., Manne U., Stockard C.R., Harkins L.E., and Srivastava S. Factors affecting immunohistochemical evaluation of biomarker expression in neoplasia. In: Hanausek M., and Walaszek Z. (Eds). Methods in molecular medicine - tumor marker protocols (1998), Humana Press, Inc., Totowa, NJ 161-179
27. Gavrieli Y., Sherman Y., and Ben-Sasson S.A. Identification of programmed cell death in situ via specific labeling of nuclear DNA fragmentation. J. Cell Biol. 119 (1992) 493-501
28. Li Y., Wang H., Wang Z., Makhija S., Buchsbaum D., LoBuglio A., Kimberly R., and Zhou T. Inducible resistance of tumor cells to tumor necrosis factor-related apoptosis-inducing ligand receptor 2-mediated apoptosis by generation of a blockade at the death domain function. Cancer Res. 66 (2006) 8520-8528
29. Armstrong D.K., Bundy B., Wenzel L., Huang H.Q., Baergen R., Lele S., Copeland L.J., et al. Intraperitoneal cisplatin and paclitaxel in ovarian cancer. N. Engl. J. Med. 354 (2006) 34-43
30. Enfeng Z., Zhou M., Caiying F., Beifen S., Zhang Q., and Lijuan L. Effects of TNF alone or in combination with chemotherapeutic agents on human ovarian cancers in vitro and in nude mice. Chin. Med. J. 108 (1995) 571-575
31. Cuello M., Ettenberg S.A., Nau M.M., and Lipkowitz S. Synergistic induction of apoptosis by the combination of TRAIL and chemotherapy in chemoresistant ovarian cancer cells. Gynecol. Oncol. 81 (2001) 380-390
32. Lane D., Cartier A., L'Esperance S., Cote M., Rancourt C., and Piche A. Differential induction of apoptosis by tumor necrosis factor-related apoptosis-inducing ligand in human ovarian carcinoma cells. Gynecol. Oncol. 93 (2004) 594-604
33. Tomek S., Horak P., Pribill I., Haller G., Rossler M., Zielinski C.C., et al. Resistance to TRAIL-induced apoptosis in ovarian cancer cell lines is overcome by cotreatment with cytotoxic drugs. Gynecol. Oncol. 94 (2004) 107-114
34. Vignati S., Codegoni A., Polato F., and Broggini M. TRAIL activity in human ovarian cancer cells: potentiation of the action of cytotoxic drugs. Eur. J. Cancer 38 (2002) 177-183
35. Sarantopoulos J., Wakelee H., Mita M., Fitzgerald A., Hill M., Fox N.L., et al. HGS-ETR2-STO2: a phase I clinical trial of HGS-ETR2, a fully human activating monoclonal antibody to TRAIL-R2, in patients with advanced solid tumors. Abstract presented at the AACR-NCI-EORTC International Conference of Molecular Targets and Cancer Therapeutics. Philadelphia, PA. Nov (2005)
36. Mom C.H., Sleijfer S., Gietema J.A., Sneller V., Fox N.L., and Lo L. A phase I study of HGS-ETR1, a fully human agonistic monoclonal antibody to the TRAIL-R1, in combination with gemcitabine and cisplatin in subjects with advanced solid malignancies. Abstract presented at the AACR-NCI-EORTC International Conference of Molecular Targets and Cancer Therapeutics. Philadelphia, PA. Nov (2005)
37. Ohtsuka T., Buchsbaum D., Oliver P., Makhija S., Kimberly R., and Zhou T. Synergistic induction of tumor cell apoptosis by death receptor antibody and chemotherapy agent through JNK/p38 and mitochondrial death pathway. Oncogene 22 (2003) 2034-2044
38. Makhija S., Ohtsuka T., Li Y., Buchsbaum D., LoBuglio A., Alvarez R., Gercel-Taylor C., and Zhou T. Expression and function of TRAIL-R1 (DR4) and TRAIL-R2 (DR5) in primary ovarian cancer cells. Abstr. Gynecol. Oncol. 88 (2003) 180